drugset / Trial / NCT03295747

Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain

NCT03295747

Phase 1 Completed 30 enrolled Robert Shulman, M.D.
RandomizedParallel-groupOpen-labelTreatment

Summary

Aim 1 - Determine the pharmacokinetics of PMO (menthol) of three different doses in children with functional abdominal pain (FAP) (n=30). Aim 2 - Determine pharmacodynamic effect of three different doses of PMO on gut microbiome composition and contractile activity/gut transit rate.

Timeline

Start
2017-10-15
Primary completion
2019-03-28
Completion
2019-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Peppermint oil Other / unclassified 180 mg Oral
Subject Peppermint oil Other / unclassified 360 mg Oral
Subject Peppermint oil Other / unclassified 540 mg Oral

Indications

No indication recorded.